Structured evidence table for Fucoidan Immune Function Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Fucoidan Immune Function Randomized Trial | For seaweed sulfated polysaccharides, however, the evidence is not yet strong enough to claim that they are bona fide trained-immunity inducers. | 3 | Liu Wei (2026) | Seaweed sulfated polysaccharides regulate the gut microbiota-mucosal barrier-innate immunity axis: structural heterogeneity, immunological evidence, and translational prospects |
| Fucoidan Immune Function Randomized Trial | The present review is organized around four interconnected levels: the major polysaccharide classes and their structural heterogeneity; their interactions with the gut microbiota and microbial enzyme systems; the innate immune and mucosal barrier pathways involved; and the disease-relevant evidence together with the key translational bottlenecks that remain to be addressed. | 3 | Liu Wei (2026) | Seaweed sulfated polysaccharides regulate the gut microbiota-mucosal barrier-innate immunity axis: structural heterogeneity, immunological evidence, and translational prospects |
| Fucoidan Immune Function Randomized Trial | The evidence was organized along a unified analytical chain, from structural features to microbial metabolism, barrier outcomes, and immune readouts, so that studies differing in source material, processing, and model systems could be compared and key knowledge gaps identified. | 3 | Liu Wei (2026) | Seaweed sulfated polysaccharides regulate the gut microbiota-mucosal barrier-innate immunity axis: structural heterogeneity, immunological evidence, and translational prospects |
| Fucoidan Immune Function Randomized Trial | 1 5 Seaweed polysaccharides are among the most mature and versatile molecular families in marine natural product research. | 3 | Liu Wei (2026) | Seaweed sulfated polysaccharides regulate the gut microbiota-mucosal barrier-innate immunity axis: structural heterogeneity, immunological evidence, and translational prospects |
Source documents